Stilla expands leadership team to drive next phase of global commercial growth; appoints Philippe Mourere as President
BOSTON, MA and PARIS, FRANCE – February 2, 2021 – Stilla Technologies is pleased to announce the appointment of Mr. Philippe Mourere as its new Chief Executive Officer. Former CEO and Founder Dr. Rémi Dangla has been appointed Chief Technology Officer and remains a member of the Board of Directors.
Stilla technologies was founded in 2013 and is a global leader in the digital PCR market. Its naica® product line includes the naica® system, microfluidic chips and reagents optimized for a wide variety of applications including liquid biopsy and COVID-19 testing. The appointment of Mr. Philippe Mourere represents a milestone in the company’s commercial evolution.
“We founded Stilla Technologies with the goal of improving healthcare by developing and providing solutions for high precision genetic analysis to researchers and clinicians worldwide. As we accelerate our commercial growth, I am pleased to be handing over the company’s leadership to Philippe who brings valuable experience for our next chapter,” commented Rémi Dangla “I remain committed to driving the company’s innovations as Chief Technology Officer and a member of the Board of Directors.”
Mourere is an experienced executive leader with over 25 years’ experience gained at leading life science and diagnostic companies including HalioDx, Ultivue, Cell Signaling Technology, PerkinElmer and Caliper Life Sciences. Mourere has delivered transformative growth across genomic and proteomic market spaces globally.